GSK has outlined a late-stage development plan for a gynecological cancer antibody-drug conjugate (ADC) licensed from Hansoh Pharma after early promising data. The UK drugmaker said it intends to initiate five separate Phase 3 studies to evaluate the asset across intended patient and disease settings. The communication positions the ADC as a potential candidate for broader clinical evaluation in gynecologic malignancies, with Phase 3 expansion reflecting confidence in the early efficacy and safety profile reported previously. For GSK, the move deepens its oncology portfolio via collaboration-enabled pipeline buildouts. For Hansoh, the five-study Phase 3 plan further reinforces the value of its ADC platform and licensing strategy with a major Western partner. The next milestone will be the start of the Phase 3 program and eventual readouts to determine the ADC’s competitive placement in gynecologic oncology.